- Home
- ZENV vs IVA Comparison
ZENV vs IVA Comparison
Compare ZENV & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- IVA
- Stock Information
- Founded
- ZENV 2005
- IVA 2011
- Country
- ZENV Brazil
- IVA France
- Employees
- ZENV N/A
- IVA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- IVA Health Care
- Exchange
- ZENV Nasdaq
- IVA Nasdaq
- Market Cap
- ZENV 63.3M
- IVA 117.3M
- IPO Year
- ZENV 2021
- IVA 2020
- Fundamental
- Price
- ZENV $1.62
- IVA $2.35
- Analyst Decision
- ZENV
- IVA Strong Buy
- Analyst Count
- ZENV 0
- IVA 4
- Target Price
- ZENV N/A
- IVA $13.25
- AVG Volume (30 Days)
- ZENV 72.4K
- IVA 9.3K
- Earning Date
- ZENV 11-18-2024
- IVA 09-25-2024
- Dividend Yield
- ZENV N/A
- IVA N/A
- EPS Growth
- ZENV N/A
- IVA N/A
- EPS
- ZENV N/A
- IVA N/A
- Revenue
- ZENV $173,594,726.00
- IVA $20,652,523.00
- Revenue This Year
- ZENV $25.56
- IVA N/A
- Revenue Next Year
- ZENV $6.02
- IVA $361.78
- P/E Ratio
- ZENV N/A
- IVA N/A
- Revenue Growth
- ZENV 23.49
- IVA N/A
- 52 Week Low
- ZENV $1.00
- IVA $1.53
- 52 Week High
- ZENV $3.88
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- IVA 36.64
- Support Level
- ZENV $1.61
- IVA $2.22
- Resistance Level
- ZENV $1.78
- IVA $2.39
- Average True Range (ATR)
- ZENV 0.12
- IVA 0.10
- MACD
- ZENV -0.00
- IVA -0.03
- Stochastic Oscillator
- ZENV 48.48
- IVA 24.76
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.